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Abstract
Background: The incidence of type 2 diabetes mellitus (T2DM) has been increasing in recent years. Sleep loss and
circadian rhythm abnormalities are thought to be one of the underlying causes of adverse metabolic health.
However, little is known about sleep-wake cycle irregularities in T2DM. The present study compared the bedtime,
waking time, and estimated sleep duration between T2DM and non-T2DM subjects.
Methods: The study subjects were 106 consecutive outpatients with lifestyle-related diseases (males/females = 56/50),
who answered a questionnaire on sleep status. Subjects were divided into two groups; non-T2DM (n= 32) and T2DM
(n= 74) subjects.
Results: T2DM subjects retired to bed on weekdays and holidays significantly later than non-T2DM subjects (23:43
versus 22:52, p=0.0032; 23:45 versus 22:53, p= 0.0038, respectively), and woke up significantly later on weekdays and
holidays, compared with non-T2DM subjects (06:39 versus 06:08, p=0.0325; 06:58 versus 06:24, p=0.0450, respectively).
There was no significant difference in the estimated sleep duration between the two groups. Daytime sleepiness was
reported significantly more commonly by T2DM subjects than non-T2DM subjects (p=0.0195).
Conclusions: Sleep-wake cycle irregularities are more common in T2DM subjects than non-T2DM. Confirmation that
such irregularity plays a role in the metabolic abnormalities of T2DM requires further investigation in the future.
Trial registration: UMIN 000002998
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Background
The etiology of type 2 diabetes mellitus (T2DM) includes
both genetic and environmental factors. The incidence of
T2DM has been increasing recently mainly due to
changes in lifestyle, such as over-eating, physical inactiv-
ity, and sleep deprivation. Sleep is a highly active and dy-
namic process, and serves immune defense in particular,
with an important role in disease resistance [1]. Several
studies have reported major differences in the frequency
of sleep disturbances between diabetics and non-diabetics
[2,3]. Patients with T2DM sleep less than the general
population [4]. The recent dramatic increase in the inci-
dence of obesity and diabetes, and the close relationship
between sleep cycles and diabetes [5], suggest detrimental
deprivation of certain sleep stages [6,7]. The endogenous
circadian clock, including the suprachiasmatic nucleus
(SCN) in the hypothalamus and peripheral oscillators in
vital organs, regulates much of our physiology and behav-
ior across the 24-h day when it is properly aligned with the
sleep-wake cycle. The SCN regulates the circadian
rhythms in glucose, corticosteroids, leptin and cardiovas-
cular systems through neural and/or humoral signals to
the pancreas, liver, adrenal glands, adipose tissues and heart
[8]. Shift work is associated with chronic misalignment be-
tween the endogenous circadian timing system and behav-
ioral cycles, including sleep-wake and fasting-feeding cycles
[9,10]. Therefore, health problems are not uncommon in
shift workers [11]. Chronic circadian misalignment has
been proposed to correlate with metabolic and cardiovas-
cular dysfunction [12-16]. However, whether disruption of
the sleep-wake pattern, i.e., sleep-wake cycle irregularity,
relates to T2DM remains to be elucidated.
The present study compared the sleeping and waking
times in subjects with and without T2DM.
Methods
Participants
Subjects were recruited from consecutive Japanese
outpatients with metabolic lifestyle-related diseases (e.g.,
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hypertension, dyslipidemia, diabetes and/or gout/
hyperurecemia), who visited the Department of Meta-
bolic Medicine, Osaka University Hospital, between
October and December 2011, and answered a question-
naire on sleep status. The exclusion criteria included
pregnant women, nursing mothers, and nighttime and/
or shift workers. Disease-related exclusion criteria
included pituitary diseases, mental disorders, and ma-
lignant diseases. The study subjects were 106 consecu-
tive outpatients (males/females = 56/50). The study was
approved by the Medical Ethics Committee of Osaka
University. All participants were Japanese and each gave a
written informed consent. This study (The Endocrine-
Metabolic Disease and Sleep Apnea Syndrome Study) is




Self-questionnaire on sleep habits
The questionnaire on sleep patterns consisted of the fol-
lowing 8 questions: bedtime on weekdays and holidays
(at half-hour intervals); waking time on weekdays and
holidays (at half-hour intervals); arousal (yes or no); day-
time sleepiness (yes or no); insomnia due to work (yes or
no); insomnia due to mental stress (yes or no). Sleep
duration (hours) =waking time – bedtime.
Anthropometric data and laboratory tests
Height (cm), weight (kg), and body mass index (BMI) in
kg/m2 were measured in the standing position. Systolic-
and diastolic- blood pressures were measured with a
standard sphygmomanometer after at least 5-min rest.
After overnight fasting, venous blood samples were col-
lected while the subject was in the supine position for
measurements of blood glucose, glycoalbumin, hemoglobin
A1c (HbA1c), triglyceride, high-density lipoprotein-
cholesterol (HDL-C), uric acid, and creatinine. Low-
density lipoprotein-cholesterol (LDL-C) was calculated
with the Friedewald equation. The value for HbA1c (%)
was estimated as National Glycohemoglobin Standardization
Program (NGSP) equivalent value (%), calculated by the for-
mula HbA1c (%)=HbA1c (Japan Diabetes Society [JDS],
%)+0.4%.
Diabetes mellitus was defined according to the criteria of
the World Health Organization and/or current treatment for
diabetes mellitus (sulfonyl ureas/biguanides/α-glucosidase
inhibitors/pioglitazone/ dipeptidyl peptidase-4 inhibitors/
glinides/insulin/glucagon-like peptide-1 analogue, n = 28/
27/23/10/14/2/17/2). Diabetic retinopathy, nephropathy
Table 1 Baseline characteristics of subjects with type 2 diabetes mellitus and control subjects (n = 106)
Control subjects (n = 32) T2DM subjects (n = 74) p value
Gender, male/female 19/13 37/37 0.4041
Age, years 62 ± 1 (39-83) 66 ± 1 (36-84) 0.5349
Job type(non/employee/individual proprietor/homemaker/others) 5/14/1/11/1 17/25/1/27/4
Body mass index, kg/m2 22.7 ± 0.7 (13.9-30.8) 24.7 ± 0.5 (17.8-34.5) 0.0153
Blood glucose, mg/dL 94 ± 3 (53-113) 128 ± 74 (52-252) <0.001
Glycoalbumin, % 14.9 ± 1.0 (12.9-16.0) 19.8 ± 0.6 (12.5-33.3) 0.0243
HbA1c (NGSP), % 5.9 ± 0.1 (5.4-6.3) 7.0 ± 0.1 (5.6-14.4) 0.0001
Systolic blood pressure, mmHg 138 ± 23 (98-174) 137 ± 2 (101-182) 0.9149
Diastolic blood pressure, mmHg 81 ± 2 (65-97) 80 ± 1 (49-105) 0.7800
Triglyceride, mg/dL 175 ± 41 (44-1231) 138 ± 10 (34-471) 0.8158
High-density lipoprotein cholesterol, mg/dL 62 ± 23 (31-121) 53 ± 2 (17-103) 0.0079
Low-density lipoprotein cholesterol, mg/dL 117 ± 5 (80-196) 112 ± 4 (64-208) 0.3333
Uric acid, mg/dL 5.5 ± 0.2 (2.8-7.8) 5.5 ± 0.2 (2.7-9.4) 0.9827
Creatinine, mg/dL 0.70 ± 0.02 (0.46-1.15) 0.86 ± 0.05 (0.44-2.83) 0.0798
Diabetic neuropathy - n = 15
Diabetic retinopathy (NDR/SDR/PDR) - n = 56/6/12
Diabetic nephropathy (stage I/II/III/IV) - n = 57/9/3/5
Drugs for diabetes (medication/insulin) - n = 57/17
Hypertension (under medications) n = 18 (n = 11) n = 60 (n = 46) 0.0151
Dyslipidemia (under medications) n = 21 (n = 13) n = 48 (n = 34) 0.8253
Insomnia, under medications n = 6 n= 11 0.7736
Data are mean ± SEM or n (range). Significant level was set at p value <0.05 (bold type). T2DM: type 2 diabetes mellitus, NDR: non-diabetic retinopathy, SDR:
simple diabetic retinopathy, PDR: proliferative diabetic retinopathy.
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and peripheral neuropathy were diagnosed as reported
previously [17]. Dyslipidemia was defined as total cholesterol
of ≥220 mg/dL, triglyceride ≥150 mg/dL, HDL-C <40 mg/
dL, and/or current treatment for dyslipidemia (statins/
fibrates/ezetimibe; n=40/4/5). Hypertension was defined as
systolic blood pressure ≥140 mmHg, diastolic blood pres-
sure ≥90 mmHg, or current treatment for hypertension
(calcium channel antagonists/angiotensin converting enzyme
inhibitors/angiotensin receptor blockers/β-blockers/α-
blockers/diuretics/ direct renin inhibitor; n = 35/5/36/8/
2/9/2).
Statistical analysis
All values were expressed as mean±SEM. In all cases, a p
value <0.05 denoted the presence of a statistically sig-
nificant difference. Differences between two groups were
compared by unpaired Student’s t-test. Differences in fre-
quencies were compared by the χ2 test. All analyses were
performed with the JMP Statistical Discovery Software
9.0 (SAS Institute, Cary, NC).
Results
Characteristics of T2DM and non-T2DM subjects
Subjects with lifestyle-related diseases were divided into
two groups; with T2DM and non-T2DM. The baseline
characteristics of the two groups are listed in Table 1.
T2DM subjects had significantly higher BMI, lower
serum HDL-C levels, higher prevalence of hypertension,
than non-T2DM subjects.
Bedtime, waking time, and sleep duration
Figure 1 is a histogram of reported bedtime on weekdays
and holidays in T2DM and non-T2DM subjects. The
bedtime on weekends and holidays was significantly later
in T2DM subjects, compared to non-T2DM subjects
(23:43±0:12 versus 22:52±0:13, p = 0.0032, Figure 1A;
23:45±0:12 versus 22:53±0:13, p = 0.0038, Figure 1B).
Figure 2 is a histogram of waking time on weekdays
and holidays in T2DM and non-T2DM subjects. The
waking time was significantly later in T2DM subjects on
weekends and holidays, compared to non-T2DM subjects
(06:39±0:08 versus 06:08±0:02, p = 0.0325, Figure 2A; 06:58
±0:08 versus 06:24±0:12, p = 0.0450, Figure 2B).
There was no significant difference in the estimated
sleep duration on weekdays and holidays between the
two groups (Figure 3).
Correlation between sleep-wake parameters and HbA1c
In bedtime analysis, the lowest HbA1c levels were 6.5±
0.1% and 6.6±0.1% recorded at bedtime 23:00–00:00 on
weekdays and on holidays, respectively (Figure 4 left,
solid box). In waking time analysis, the lowest HbA1c
levels were 6.7±0.1% and 6.6±0.1% in waking time
<06:00 on weekdays and holidays, respectively (Figure 4
middle, solid box). In sleep duration analysis, the lowest
HbA1c levels were 6.4±0.1% and 6.4±0.2% in subjects
who slept for 7–8 h on weekdays and holidays, respectively
(Figure 4 right, solid box).
Incidence of sleep-related problems
The prevalence of daytime sleepiness was significantly
higher in T2DM subjects than in non-T2DM subjects
(46% versus 22%, p = 0.0195, Figure 5). However, there
were no significant differences in the frequency of arousals
at night or percentages of subjects with work- and mental
stress-related insomnia between the two groups.
Discussion
The major findings of the present study were that T2DM
subjects retired to bed later and woke up later, and suf-
fered from daytime sleepiness, compared with non-
T2DM subjects. The 2006 Ministry of Internal Affairs
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Figure 1 Histograms of the numbers of subjects with type 2
diabetes mellitus (DM+) and non-diabetic subjects (DM-) for
each bedtime on (A) weekdays and (B) holidays.
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and Leisure Activities indicates that the average bedtime
of 66,428 Japanese (males/females; 31,520/34,908) is
23:16 on weekdays, with waking time on weekdays of
06:39. Comparison of the above data and the present
findings confirm that the Japanese T2DM subjects
tended to retire to bed relatively later than the rest of
the population.
The circadian system is linked to various processes
that control both sleep and metabolism. The sleep-wake
cycle and fasting-feeding behavior are considered to be
regulated by the circadian clock [14-16]. Experimental
models of the clock gene have demonstrated the devel-
opment of metabolic disorders, such as obesity and
T2DM, after disruption of the circadian rhythms [18-22].
However, whether abnormal glucose metabolism has any
impact on the circadian rhythm remains unclear. A vi-
cious cycle may ensue in the disrupted glucose metabolic
pathways, leading to lengthening of the circadian oscilla-
tion abnormality. Scheer et al. showed that diurnal vari-
ation of neurohumoral factors, such as leptin and cortisol,
plays a role in behavioral cycles (fasting/feeding and
sleep/wake cycles) [13]. Further studies are required to
investigate circadian variation of neurohumoral factors
in blood. In this regard, the present work is a cross-
sectional study, making it difficult to establish a cause-
effect relationship. Sleep management, e.g., lifestyle modi-
fication by trained medical staff and use of exogenous
melatonin as a potential chronotherapeutic agent, may
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Figure 3 Histograms of the numbers of subjects with type 2
diabetes mellitus (DM+) and non-diabetic subjects (DM-) for
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Figure 2 Histograms of the numbers of subjects with type 2
diabetes mellitus (DM+) and non-diabetic subjects (DM-) for
each waking time on (A) weekdays and holidays (B).
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system in T2DM subjects with sleep-wake irregularities.
Further prospective interventional studies should be con-
ducted in the future to investigate this relationship.
Patients with T2DM sleep less than the general popu-
lation [4]. A gradual decrease in self-reported sleep dur-
ation seems to have occurred with the dramatic recent
increase in the incidence of obesity and diabetes, includ-
ing a close relationship between sleep cycle and diabetes
[23-25]. However, the present study found no significant
difference in the sleep duration between the diabetics
and non-diabetic subjects (Figure 3). However, records of
bedtime and waking time were based in the present
study on information provided by the subjects, and
therefore the sleep duration may be inaccurate.
Previous studies reported that both short (<5 h) and
long (>9 h) sleepers as well as those with sleep loss, are at
greater risk for glucose intolerance and T2DM [26-33].
The present study found that late bedtime (>1:00) sleepers
as well as short and long sleepers had elevated HbA1c
(Figure 4). Taken together, irregular sleep-wake patterns as
well as short and long sleep may enhance glucose
dysmetabolism.
Conclusion
The present study demonstrated late bedtime and late
wake-up time, with daytime sleepiness in T2DM subjects,
compared with non-T2DM subjects. Early retirement to
sleep and early morning rise seems potentially simple and
useful therapeutic target for diabetes.
Study limitations
There are several limitations to this study. First, all
outpatients in this study were Japanese and any differences
from other ethnicities are unknown. Second, there is bias
in single center studies. Our study included only a limited
number of subjects and further multi-center studies of lar-
ger samples should be conducted in the future. Finally, the
percentage of non-employees among diabetics was 23.0%
(n=17/74), compared to those among non-diabetics (n= 5/
32, 15.6%) (Table 1), although there was no significant dif-
ference between two groups (p=0.4824). Diabetics often
perform the capillary blood sugar self-test before go to bed.
These points may influence the results.
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Figure 5 Comparisons of the frequency of reported arousals,
daytime sleepiness, insomnia (due to work) and insomnia (due
to mental stress) in subjects with type 2 diabetes mellitus (DM
+) and non-diabetic subjects (DM-).
Figure 4 Mean HbA1c levels at various bed and waking times, and according to sleep duration on weekdays (top) and holidays
(bottom). Data are mean±SEM.
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